Loading…
Climb Bio, Inc. is projected to rise to $18.34 by 2027, a +53% move from its current price of $11.96. CLYM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $11.47 | $11.97 | $12.50 | +0.10% |
| May 30 | $11.28 | $11.98 | $12.74 | +0.20% |
| May 31 | $11.13 | $12.00 | $12.93 | +0.30% |
| Jun 1 | $11.02 | $12.01 | $13.09 | +0.41% |
| Jun 2 | $10.92 | $12.02 | $13.24 | +0.51% |
| Jun 3 | $10.83 | $12.03 | $13.37 | +0.61% |
| Jun 4 | $10.75 | $12.05 | $13.50 | +0.71% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.75 | $12.05 | $13.50 | +0.71% |
| Week 2 | $10.33 | $12.13 | $14.25 | +1.43% |
| Week 3 | $10.03 | $12.22 | $14.88 | +2.15% |
| Week 4 | $9.80 | $12.30 | $15.45 | +2.88% |
| Week 5 | $9.60 | $12.39 | $15.99 | +3.61% |
| Week 6 | $9.44 | $12.48 | $16.50 | +4.35% |
| Week 7 | $9.30 | $12.57 | $16.99 | +5.10% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
In addition, the company is developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc.
and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Climb Bio, Inc. (CLYM) is a healthcare-focused biotechnology company operating in the field of immune-mediated diseases. Current price: $11.96; market cap: $684.84M; rank: 2778.
A major floor 64.7% below — a decisive break under it would weaken the trend.
The nearest floor, 27.7% below — buyers have tended to step in here.
Price is pressing into resistance (2.2% away) — a breakout level to watch.
A major ceiling 21.3% above — clearing it would confirm fresh momentum.
Key CLYM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLYM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.16 | Buy | $11.28 | Buy |
| MA 10 | $10.89 | Buy | $11.01 | Buy |
| MA 20 | $10.72 | Buy | $10.59 | Buy |
| MA 50 | $8.97 | Buy | $9.29 | Buy |
| MA 100 | $7.26 | Buy | $7.66 | Buy |
| MA 200 | $4.79 | Buy | $5.84 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.87 | Neutral |
| Stoch RSI (14) | 63.12 | Neutral |
| CCI (20) | 95.07 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | 5.19 | Buy |
| Bollinger %B (20,2) | 0.80 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 1.03 | Buy |
| Awesome (5,34) | 1.17 | Buy |
| Ultimate (7,14,28) | 60.87 | Neutral |
| Momentum (10) | 0.79 | Buy |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 11.61 | Buy |
| ADX (14) | 26.59 | Buy |
| ATR (14) | 0.41 | Info |
The company sits in the Healthcare category and is currently trading around the mid-teens in price. Its 30-day technical picture is bullish, with an RSI14 of 70, a SMA50 of $8.97 and a SMA200 of $4.79. Key near-term levels include support at $8.65 and resistance at $12.22, with a 30-day price range of $9.00 to $15.89.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.54 | $11.96 | $19.37 | 0% | Neutral | |
| $13.73 | $18.34 | $26.35 | +53% | Bullish | |
| $14.65 | $20.48 | $31.00 | +71% | Bullish | |
| $16.00 | $23.26 | $36.66 | +94% | Bullish | |
| $15.27 | $23.00 | $37.50 | +92% | Bullish | |
| $15.65 | $24.34 | $40.88 | +104% | Bullish | |
| $20.93 | $33.57 | $57.87 | +181% | Bullish | |
| $24.66 | $40.74 | $71.90 | +241% | Bullish | |
| $27.11 | $46.07 | $83.09 | +285% | Bullish | |
| $27.08 | $47.31 | $87.04 | +296% | Bullish | |
| $43.07 | $85.60 | $171.08 | +616% | Bullish | |
| $58.50 | $130.00 | $292.31 | +987% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.54 | $11.96 | $14.11 | +0.00% |
| June 2026 | $10.14 | $12.06 | $14.80 | +0.84% |
| July 2026 | $10.88 | $13.12 | $16.43 | +8.77% |
| August 2026 | $11.34 | $13.82 | $17.58 | +5.31% |
| September 2026 | $11.15 | $13.71 | $17.66 | -0.79% |
| October 2026 | $11.38 | $14.10 | $18.38 | +2.86% |
| November 2026 | $11.87 | $14.81 | $19.50 | +5.05% |
| December 2026 | $11.59 | $14.57 | $19.37 | -1.64% |
Click any year to see its month-by-month CLYM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CLYM price prediction for 2026 points to an average of $11.96 (low $3.54, high $19.37) — a potential gain of 0% on today's $11.96. Price action looks broadly range-bound.
In 2027, CLYM is projected to trade between $13.73 and $26.35, averaging $18.34 — a potential gain of +53% from today's $11.96. That is up +53% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Climb Bio, Inc.'s 2028 outlook centres on $20.48, within a $14.65 to $31.00 range. That is up +12% on the projected 2027 average. That marks a +71% change versus current levels. Momentum favours further upside here.
By 2029, CLYM could reach as high as $36.66, with a base case around $23.26 and support toward $16.00 — roughly +94% from $11.96. Buyers look set to stay in control over this stretch.
Expect CLYM to range from $15.27 to $37.50 through 2030. The $23.00 average target implies a +92% move from current prices. That is -1% versus the projected 2029 average. Momentum favours further upside here.
The CLYM price prediction for 2031 points to an average of $24.34 (low $15.65, high $40.88) — a potential gain of +104% on today's $11.96. Buyers look set to stay in control over this stretch.
In 2032, CLYM is projected to trade between $20.93 and $57.87, averaging $33.57 — a potential gain of +181% from today's $11.96. That is up +38% on the projected 2031 average. Momentum favours further upside here.
Climb Bio, Inc.'s 2033 outlook centres on $40.74, within a $24.66 to $71.90 range. That is up +21% on the projected 2032 average. That marks a +241% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, CLYM could reach as high as $83.09, with a base case around $46.07 and support toward $27.11 — roughly +285% from $11.96. Momentum favours further upside here.
Expect CLYM to range from $27.08 to $87.04 through 2035. The $47.31 average target implies a +296% move from current prices. That is up +3% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The CLYM price prediction for 2040 points to an average of $85.60 (low $43.07, high $171.08) — a potential gain of +616% on today's $11.96. Momentum favours further upside here.
In 2050, CLYM is projected to trade between $58.50 and $292.31, averaging $130.00 — a potential gain of +987% from today's $11.96. That is up +52% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CLYM today (≈ 83.61204 CLYM) could be worth
$10,869.42
+$9,869.42 (+987%) by 2050 · US Dollar
Based on the average projected CLYM price of $130 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLYMwould be worth at today's price.
$1,000 invested in CLYM on May 27, 2025 (≈ 854.700886 CLYM) would be worth
$10,222.22
+$9,222.22 (+922.2%) today · 10.22× · US Dollar
Based on a CLYM entry price of $1.17 vs. today's $11.96.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.52 | $1,136.88 | +13.7% |
| 1 month ago | $9.5 | $1,258.95 | +25.9% |
| 3 months ago | $7.38 | $1,620.6 | +62.1% |
| 6 months ago | $1.89 | $6,328.04 | +532.8% |
| 1 year ago | $1.17 | $10,222.22 | +922.2% |
| All time (4.8y) ago | $15.9 | $752.2 | -24.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLYM forecast.
Our base-case forecast reaches $24.00 around 2031.
Implied market cap at $24.00: $1.37B
The multi-year forecast sketches a strong upside trajectory, with 2026–2035 showing rising averages and sizable ROIs. Notably, the 2030 average is 23.00 with an ROI of 92.3 and a 2030 min of 15.27 and max of 37.50. The forecast continues to 2040 with an average of 85.60 and an ROI of 615.7, and culminates in 2050 with an average of 130.00 and an ROI of 986.9.
These figures imply meaningful long-term upside if the clinical program advances as anticipated, though outcomes remain dependent on clinical progress and regulatory developments.
Tap a question to reveal the answer.
2030 forecast: min 15.27, avg 23.00, max 37.50; ROI 92.3.
The forecast shows bullish sentiment across multiple years, with rising averages and ROIs (e.g., 2027 avg 18.34, ROI 53.3; 2050 avg 130.00, ROI 986.9). These are estimates and not guarantees.
Yes. The forecast for 2035 max is 87.04 and 2040 max is 171.08, indicating potential to exceed $60 in those years.
Current price: $11.96; market cap: $684.84M.
30-day range: $9.00–$15.89; RSI14: 70; SMA50: 8.97; SMA200: 4.79; support: 8.65; resistance: 12.22.
Climb Bio, Inc. Community Discussion
0Share your Climb Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.